1. bookTom 58 (2020): Zeszyt 2 (June 2020)
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
2501-062X
Pierwsze wydanie
30 Mar 2015
Częstotliwość wydawania
4 razy w roku
Języki
Angielski
Otwarty dostęp

Pharmacogenomics: introduction and use in clinical practice

Data publikacji: 02 Jun 2020
Tom & Zeszyt: Tom 58 (2020) - Zeszyt 2 (June 2020)
Zakres stron: 69 - 74
Otrzymano: 28 Jan 2020
Informacje o czasopiśmie
License
Format
Czasopismo
eISSN
2501-062X
Pierwsze wydanie
30 Mar 2015
Częstotliwość wydawania
4 razy w roku
Języki
Angielski

1. ORRICO K., Basic concepts in genetics and pharmacogenomics for pharmacists, Drug Target Insights, 2019, doi: 10.1177/1177392819886875.10.1177/1177392819886875Search in Google Scholar

2. 2019, Table of pharmocaogenomic Biomarkers in Drug Labelling. FDA. Viewed: 12/11/2019, https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm.Search in Google Scholar

3. MAREZ D., LEGRAND M., SABBAGH N., LO GUIDICE J.M., SPIRE C., LAFITTE J.J. et al., Polymorphism of the cytochrome P450 CYP2D6 in a European population: Characterization of 48 mutations of 53 alleles, their frequencies and evolution, Pharmacogenetics, 1997, 7(3): 193.Search in Google Scholar

4. KELLY L., RIEDER M., VAN DEN ANKER J., MALKIN B., ROSS C., NEELY M.N. et al., More codeine fatalities after tonsillectomy in North American children, Pediatrics, 2012, 129(5).10.1542/peds.2011-2538Search in Google Scholar

5. GOETZ M., SANGKUHL K., GUCHELAAR H.J., SCHWAB M., PROVINCE M., WHIRL-CARRILLO M. et al., Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy, Clin. Pharmacol. Ther., 2018, 103(5):770–777.Search in Google Scholar

6. RAY S., Clopidogrel resistance: The way forward, Indian heart journal, 2014, 66(5):530–534.Search in Google Scholar

7. RUSH A.J., FAVA M., WISNIEWSKI S.R., LAVORI P.W., TRIVEDI M.H., SACKEIM H.A. et al., Sequenced Treatment Alternatives to Relieve Depression. Control clin trials, 2004, 25(1):119–142.10.1016/S0197-2456(03)00112-0Search in Google Scholar

8. EVANS W.E., HON Y.Y., BOMGAARS L., COUTRE S., HOLDSWORTH M., JANCO R. et al., Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine, Journal of Clinical Oncology, 2001, 19(8):2293–2301.Search in Google Scholar

9. RELLING M. et al., Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2018 update, CIPC update, 2018.Search in Google Scholar

10. BRUNHAM L. et al., Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence, Cardiovasc. Res., 2018, 114(8):1073.Search in Google Scholar

11. TARAVES L. et al., Genotype-guided warfarin therapy: The current status, Pharmacogenomics, 2018, 19(7):667–685.Search in Google Scholar

12. 2019, Direct-To-Consumer Testing. FDA. Viewed: 12/25/2019 https://www.fda.gov/medical-devices/vitro-diagnostics/direct-consumer-tests#listSearch in Google Scholar

13. SHAH R., SMITH R., Addressing phenoconversion: The Achillies’ heel of personalised medicine, Brit. J. Clin. Pharmacol., 2015, 79(2):222–240.Search in Google Scholar

Polecane artykuły z Trend MD

Zaplanuj zdalną konferencję ze Sciendo